cd25 apc (Elabscience Biotechnology)
Elabscience Biotechnology is a verified supplier 
Elabscience Biotechnology manufactures this product 
94
Structured Review
Elabscience Biotechnology
cd25 apc
Cd25 Apc, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 43 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd25/APC+Anti-Mouse+CD25+Antibody/pmc12840754-251-89-90
Average 94 stars, based on 43 article reviews
Cd25 Apc, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 43 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd25/APC+Anti-Mouse+CD25+Antibody/pmc12840754-251-89-90
Average 94 stars, based on 43 article reviews
cd25 apc - by Bioz Stars,
2026-11
94/100 stars
Images
Related Articles
other:Article Title: Cyclophosphamide-Mediated Induction of Myeloid-Derived Suppressor Cells In Vivo: Kinetics of Accumulation, Immune Profile, and Immunomodulation by Oleanane-Type Triterpenoids Article Snippet: Monoclonal anti-mouse antibodies: anti-CD16/CD32 (BD Biosciences, #553142, clone 2.4G2, San Diego, CA, USA), CD45-FITC (BD Biosciences, #553080, clone 30-F11, San Diego, CA, USA), Article Title: Gallic acid/copper ion-based metal-phenolic networks as photothermal-enhanced nanocatalysts for cancer therapy Article Snippet: HKOH-1 and Monobromobimane (MBB) were acquired from MedChem Express (Shanghai, China). Article Title: Cyclophosphamide-Mediated Induction of Myeloid-Derived Suppressor Cells In Vivo: Kinetics of Accumulation, Immune Profile, and Immunomodulation by Oleanane-Type Triterpenoids. Article Snippet: Monoclonal anti-mouse antibodies: anti-CD16/CD32 (BD Biosciences, #553142, clone 2.4G2, San Diego, CA, USA), CD45-FITC (BD Biosciences, #553080, clone 30-F11, San Diego, CA, USA), Activation Assay:Article Title: Local therapeutic platform prevents postsurgical GBM recurrence by diminishing GICs and reshaping immunosuppressive microenvironment Article Snippet: .. The following antibody panels were used: anti-CD3-FITC (E-AB-F1013C, Elabscience), anti-CD4-PE (E-AB-F1097D, Elabscience), and anti-CD8-Percp Cy5.5 (E-AB-F1104J, Elabscience) for CD4 + /CD8 + T-cell analysis; anti-CD11c-FITC (E-AB-F0991C, Elabscience), anti-CD80-APC (E-AB-F0992E, Elabscience), and anti-CD86-PE (E-AB-F0994D, Elabscience) for DC cell detection; anti-CD3-FITC (E-AB-F1013C, Elabscience), Article Title: Local therapeutic platform prevents postsurgical GBM recurrence by diminishing GICs and reshaping immunosuppressive microenvironment. Article Snippet: .. The following antibody panels were used: anti-CD3-FITC (E-AB-F1013C, Elabscience), anti-CD4-PE (E-AB-F1097D, Elabscience), and anti-CD8-Percp Cy5.5 (E-AB-F1104J, Elabscience) for CD4+/CD8+ T-cell analysis; antiAR TI CL E IN P RE SS CD11c-FITC (E-AB-F0991C, Elabscience), anti-CD80-APC (E-AB-F0992E, Elabscience), and anti-CD86-PE (E-AB-F0994D, Elabscience) for DC cell detection; anti-CD3-FITC (E-ABF1013C, Elabscience), Cell Analysis:Article Title: Local therapeutic platform prevents postsurgical GBM recurrence by diminishing GICs and reshaping immunosuppressive microenvironment Article Snippet: .. The following antibody panels were used: anti-CD3-FITC (E-AB-F1013C, Elabscience), anti-CD4-PE (E-AB-F1097D, Elabscience), and anti-CD8-Percp Cy5.5 (E-AB-F1104J, Elabscience) for CD4 + /CD8 + T-cell analysis; anti-CD11c-FITC (E-AB-F0991C, Elabscience), anti-CD80-APC (E-AB-F0992E, Elabscience), and anti-CD86-PE (E-AB-F0994D, Elabscience) for DC cell detection; anti-CD3-FITC (E-AB-F1013C, Elabscience), Article Title: Local therapeutic platform prevents postsurgical GBM recurrence by diminishing GICs and reshaping immunosuppressive microenvironment. Article Snippet: .. The following antibody panels were used: anti-CD3-FITC (E-AB-F1013C, Elabscience), anti-CD4-PE (E-AB-F1097D, Elabscience), and anti-CD8-Percp Cy5.5 (E-AB-F1104J, Elabscience) for CD4+/CD8+ T-cell analysis; antiAR TI CL E IN P RE SS CD11c-FITC (E-AB-F0991C, Elabscience), anti-CD80-APC (E-AB-F0992E, Elabscience), and anti-CD86-PE (E-AB-F0994D, Elabscience) for DC cell detection; anti-CD3-FITC (E-ABF1013C, Elabscience), Staining:Article Title: Cancer Immunomodulatory Effect of Bidens pilosa L. in Mice: Suppression of Tumor-Associated Macrophages and Regulatory T Cells Article Snippet: .. Induced Tregs treated with or without samples were resuspended in PBS and stained with Article Title: Systems-level molecular and immunological evidence identifies Th17/Treg modulation as a key mechanism of CRSJ’s neuroprotection in Parkinson’s disease Article Snippet: After stimulation, cells were fixed and permeabilized using the FoxP3/Transcription Factor Staining Buffer Kit (LianKe, No. IC001). .. For Treg staining, cells were incubated with FITC-conjugated anti-CD4 (Elabscience, No. E-AB-F1353C), Article Title: Mucosal Gingipain Vaccine Based on Framework Nucleic Acid Engineering for the Treatment of Periodontitis. Article Snippet: Periodontitis is a chronic inflammatory disease driven by oral microbial dysbiosis and dysregulated host immunity, in which Porphyromonas gingivalis (Pg) and its lysine-specific gingipain (Kgp) are key pathogenic factors.. Although immune targeting of Kgp holds promise for interrupting disease progression, inefficient transmucosal antigen delivery and limited dendritic cell (DC) activation hinder effective mucosal and humoral immune responses.. Here, we report a sublingual mucosal nanovaccine based on tetrahedral framework nucleic acids (tFNAs) for precise DC-directed immunomodulation. Incubation:Article Title: Systems-level molecular and immunological evidence identifies Th17/Treg modulation as a key mechanism of CRSJ’s neuroprotection in Parkinson’s disease Article Snippet: After stimulation, cells were fixed and permeabilized using the FoxP3/Transcription Factor Staining Buffer Kit (LianKe, No. IC001). .. For Treg staining, cells were incubated with FITC-conjugated anti-CD4 (Elabscience, No. E-AB-F1353C), Cell Stimulation:Article Title: Mucosal Gingipain Vaccine Based on Framework Nucleic Acid Engineering for the Treatment of Periodontitis. Article Snippet: Periodontitis is a chronic inflammatory disease driven by oral microbial dysbiosis and dysregulated host immunity, in which Porphyromonas gingivalis (Pg) and its lysine-specific gingipain (Kgp) are key pathogenic factors.. Although immune targeting of Kgp holds promise for interrupting disease progression, inefficient transmucosal antigen delivery and limited dendritic cell (DC) activation hinder effective mucosal and humoral immune responses.. Here, we report a sublingual mucosal nanovaccine based on tetrahedral framework nucleic acids (tFNAs) for precise DC-directed immunomodulation. Control:Article Title: Mucosal Gingipain Vaccine Based on Framework Nucleic Acid Engineering for the Treatment of Periodontitis. Article Snippet: Periodontitis is a chronic inflammatory disease driven by oral microbial dysbiosis and dysregulated host immunity, in which Porphyromonas gingivalis (Pg) and its lysine-specific gingipain (Kgp) are key pathogenic factors.. Although immune targeting of Kgp holds promise for interrupting disease progression, inefficient transmucosal antigen delivery and limited dendritic cell (DC) activation hinder effective mucosal and humoral immune responses.. Here, we report a sublingual mucosal nanovaccine based on tetrahedral framework nucleic acids (tFNAs) for precise DC-directed immunomodulation. Lysis:Article Title: Mucosal Gingipain Vaccine Based on Framework Nucleic Acid Engineering for the Treatment of Periodontitis. Article Snippet: Periodontitis is a chronic inflammatory disease driven by oral microbial dysbiosis and dysregulated host immunity, in which Porphyromonas gingivalis (Pg) and its lysine-specific gingipain (Kgp) are key pathogenic factors.. Although immune targeting of Kgp holds promise for interrupting disease progression, inefficient transmucosal antigen delivery and limited dendritic cell (DC) activation hinder effective mucosal and humoral immune responses.. Here, we report a sublingual mucosal nanovaccine based on tetrahedral framework nucleic acids (tFNAs) for precise DC-directed immunomodulation. Flow Cytometry:Article Title: Mucosal Gingipain Vaccine Based on Framework Nucleic Acid Engineering for the Treatment of Periodontitis. Article Snippet: Periodontitis is a chronic inflammatory disease driven by oral microbial dysbiosis and dysregulated host immunity, in which Porphyromonas gingivalis (Pg) and its lysine-specific gingipain (Kgp) are key pathogenic factors.. Although immune targeting of Kgp holds promise for interrupting disease progression, inefficient transmucosal antigen delivery and limited dendritic cell (DC) activation hinder effective mucosal and humoral immune responses.. Here, we report a sublingual mucosal nanovaccine based on tetrahedral framework nucleic acids (tFNAs) for precise DC-directed immunomodulation. Purification:Article Title: Mucosal Gingipain Vaccine Based on Framework Nucleic Acid Engineering for the Treatment of Periodontitis. Article Snippet: Periodontitis is a chronic inflammatory disease driven by oral microbial dysbiosis and dysregulated host immunity, in which Porphyromonas gingivalis (Pg) and its lysine-specific gingipain (Kgp) are key pathogenic factors.. Although immune targeting of Kgp holds promise for interrupting disease progression, inefficient transmucosal antigen delivery and limited dendritic cell (DC) activation hinder effective mucosal and humoral immune responses.. Here, we report a sublingual mucosal nanovaccine based on tetrahedral framework nucleic acids (tFNAs) for precise DC-directed immunomodulation. Immunopeptidomics:Article Title: Mucosal Gingipain Vaccine Based on Framework Nucleic Acid Engineering for the Treatment of Periodontitis. Article Snippet: Periodontitis is a chronic inflammatory disease driven by oral microbial dysbiosis and dysregulated host immunity, in which Porphyromonas gingivalis (Pg) and its lysine-specific gingipain (Kgp) are key pathogenic factors.. Although immune targeting of Kgp holds promise for interrupting disease progression, inefficient transmucosal antigen delivery and limited dendritic cell (DC) activation hinder effective mucosal and humoral immune responses.. Here, we report a sublingual mucosal nanovaccine based on tetrahedral framework nucleic acids (tFNAs) for precise DC-directed immunomodulation. |
